CXCL9 Is a Potential Biomarker of Immune Infiltration Associated With Favorable Prognosis in ER-Negative Breast Cancer

Frontiers in Oncology

Si-qi Qiu¹  Yu-zhu Qi²  De Zeng³  Ying-sheng Xiao⁴  Ze-kun- Deng⁵  Yuan-ke Liang⁶  Hao-yu Lin⁶  Mu-tong Chen⁷  Shi-cheng Jia⁷  Zheng-hao Wang⁷  Qin Xie⁷ 

[1] Clinical Research Center, Diagnosis and Treatment Center of Breast Diseases, Shantou Central Hospital, Shantou, China;Department of Hematology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen, Netherlands;Department of Medical Oncology, Cancer Hospital of SUMC, Shantou, China;Department of Thyroid Surgery Shantou Central Hospital, Shantou, China;Department of Thyroid and Breast Surgery, Clinical Research Center, The First Affiliated Hospital of Shantou University Medical College (SUMC), Shantou, China;Guangdong Provincial Key Laboratory for Diagnosis and Treatment of Breast Cancer, Shantou, China;SUMC, Shantou, China;

关键词: breast cancer;    CXCL9;    biomarker;    prognosis;    immune infiltration;   

DOI  :  10.3389/fonc.2021.710286

来源: DOAJ

【 摘 要 】

The chemokine CXCL9 (C-X-C motif chemokine ligand 9) has been reported to be required for antitumour immune responses following immune checkpoint blockade. In this study, we sought to investigate the potential value of CXCL9 according to immune responses in patients with breast cancer (BC). A variety of open-source databases and online tools were used to explore the expression features and prognostic significance of CXCL9 in BC and its correlation with immune-related biomarkers followed by subsequent verification with immunohistochemistry experiments. The CXCL9 mRNA level was found to be significantly higher in BC than in normal tissue and was associated with better survival outcomes in patients with ER-negative tumours. Moreover, CXCL9 is significantly correlated with immune cell infiltration and immune-related biomarkers, including CTLA4, GZMB, LAG3, PDCD1 and HAVCR2. Finally, we performed immunohistochemistry with breast cancer tissue samples and observed that CXCL9 is highly expressed in the ER-negative subgroup and positively correlated with the immune-related factors LAG3, PD1, PDL1 and CTLA4 to varying degrees. These findings suggest that CXCL9 is an underlying biomarker for predicting the status of immune infiltration in ER-negative breast cancer.

【 授权许可】

Unknown